Rhini Shield TX4

Company: Elanco (Farm Animal)

Bordetella Bronchiseptica-Erysipelothrix Rhusiopathiae-Pasteurella Multocida Bacterin-Toxoid

For Use In Animals Only

Rhini Shield TX4 Indications

This product has been shown to be effective for vaccination of healthy pregnant swine to provide passive immunity against atrophic rhinitis caused by Bordetella Bronchiseptica and by the toxin of Pasteurella multocida Type D when piglets are also vaccinated at 7 days of age. This product has also been shown to be effective for vaccination of healthy swine, 7 days of age or older, against pneumonia caused by Pasteurella multocida Type A and against erysipelas caused by Erysipelothrix rhusiopathiae. The duration of immunity for this product has not been established. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.

ADJUVANT: Aluminum hydroxide.

Directions For Use

Administer intramuscularly or subcutaneously. For atrophic rhinitis caused by Bordetella bronchiseptica, vaccinate gilts and sows with a 5 mL dose at 5 and 2 weeks prior to farrowing.

For atrophic rhinitis caused by Pasteurella multocida Type D, vaccinate piglets from vaccinated dams with a 1 mL dose at 7 to 10 days of age and a 2 mL dose 2 weeks later. For erysipelas caused by Erysipelothrix rhusiopathiae vaccinate piglets with single 1 mL dose at 7 to 10 days of age. For pneumonia caused by Pasteurella multocida Type A, vaccinated piglets need to receive an additional 2 mL dose 2 weeks later. The need for annual booster vaccinations has not been established for this product; consultation with a veterinarian is recommended. For advice on revaccination frequency, in general or in the face of maternal antibody, stress, or a disease exposure, consultation with a veterinarian is recommended.

Precautions

Store out of direct sunlight at 2 to 8°C (35° to 46°F). DO NOT FREEZE. Do not mix with other products, except as specified on the label. Use entire contents when first opened. Do not vaccinate within 21 days prior to slaughter. In case of human exposure, contact a physician. Anaphylactic reactions may occur. Symptomatic treatment: Epinephrine.

VLN/PCN 196/7054.01

Elanco US Inc., Fort Dodge, IA 50501 USA; 1-800-428-4441

Rhini Shield, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

CPN: 1114037.10